{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent%2C+CNS+Tumor%2C+Childhood&page=4", "query": { "condition": "Recurrent, CNS Tumor, Childhood", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 161, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent%2C+CNS+Tumor%2C+Childhood&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent%2C+CNS+Tumor%2C+Childhood&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T13:07:02.645Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01217437", "title": "Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Neoplasm", "Pineoblastoma", "Recurrent Medulloblastoma", "Recurrent Primitive Neuroectodermal Tumor", "Refractory Medulloblastoma", "Refractory Peripheral Primitive Neuroectodermal Tumor" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 108, "start_date": "2010-11-22", "completion_date": "2021-06-30", "has_results": true, "last_update_posted_date": "2021-07-23", "last_synced_at": "2026-10-21T13:07:02.645Z", "location_count": 136, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 103 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217437" }, { "nct_id": "NCT00053118", "title": "Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma", "Neuroblastoma", "Retinoblastoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 1, "start_date": "2002-03", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2011-03-01", "last_synced_at": "2026-10-21T13:07:02.645Z", "location_count": 3, "location_summary": "St Louis, Missouri • Buffalo, New York • Houston, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053118" }, { "nct_id": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Histiocytic Sarcoma", "Juvenile Xanthogranuloma", "Langerhans Cell Histiocytosis", "Malignant Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Soft Tissue Sarcoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Rhabdoid Tumor", "Stage III Osteosarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Osteosarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Osteosarcoma AJCC v7", "Stage IVB Osteosarcoma AJCC v7", "Wilms Tumor" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Samotolisib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tipifarnib", "type": "DRUG" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1377, "start_date": "2017-07-31", "completion_date": "2027-01-06", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-21T13:07:02.645Z", "location_count": 168, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155620" }, { "nct_id": "NCT00387920", "title": "Sunitinib in Treating Young Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Central Nervous System Metastases", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Embryonal Tumor", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 35, "start_date": "2006-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-28", "last_synced_at": "2026-10-21T13:07:02.645Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00387920" }, { "nct_id": "NCT06193759", "title": "Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Medulloblastoma, Childhood", "Atypical Teratoid/Rhabdoid Tumor of CNS", "Embryonal Tumor With Multilayered Rosettes", "Pineoblastoma", "Embryonal Brain Tumor Not Otherwise Specified", "Recurrent Ependymoma" ], "interventions": [ { "name": "Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)", "type": "BIOLOGICAL" }, { "name": "Group A Standard-of-Care Backbone Therapy", "type": "DRUG" }, { "name": "Group B Salvage Backbone Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 12, "start_date": "2024-09-20", "completion_date": "2032-12-29", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-21T13:07:02.645Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06193759" }, { "nct_id": "NCT00107185", "title": "Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 7, "start_date": "2005-01", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2020-08-05", "last_synced_at": "2026-10-21T13:07:02.645Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107185" }, { "nct_id": "NCT03299309", "title": "PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Medulloblastoma", "Recurrent Brain Tumor, Childhood", "Malignant Glioma" ], "interventions": [ { "name": "PEP-CMV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniel Landi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "3 Years to 35 Years" }, "enrollment_count": 30, "start_date": "2018-06-29", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-21T13:07:02.645Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03299309" }, { "nct_id": "NCT00138216", "title": "Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 42, "start_date": "2005-10", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2023-10-02", "last_synced_at": "2026-10-21T13:07:02.645Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Orange, California • Stanford, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00138216" }, { "nct_id": "NCT02415153", "title": "Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neurofibromatosis Type 1", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "3 Years to 20 Years" }, "enrollment_count": 29, "start_date": "2015-07-14", "completion_date": "2020-05-27", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-10-21T13:07:02.645Z", "location_count": 12, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02415153" }, { "nct_id": "NCT00363272", "title": "Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Burkitt Lymphoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Spinal Cord Neoplasm", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ispinesib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 30, "start_date": "2006-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-21T13:07:02.645Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363272" } ] }